Live Analyst Rating Changes 1619 upgrades, downgrades & price-target moves · freshest Wall Street data, updated daily View live feed →
Analyst Tracker/Jack Lin
MS
Jack Lin
Morgan Stanley
Wall Street Analyst
Not yet ranked — too few measurable calls.
0%
Success Rate
-25.9%
Average Return
0 of 2 calls profitable · -32.0% vs benchmark
📈 Across the calls we could measure, roughly 0% of Jack Lin's ratings turned a profit when each position was held for 1 year — averaging -25.9% per rating. These figures are computed by 13Foresight from historical prices, not supplied by the analyst.

Rating Distribution

11 Buy 6 Hold 4 Sell
Jack's Stock Coverage 12 ratings · 2026-06-22
Company Date Position Consensus ⓘ Price Target ⓘ 1-Yr Return
HK:9969
InnoCare Pharma Ltd.
 May 28, 2026 BUY Strong Buy
+79.1% avg upside
3 analysts
$17.00
56.93% Upside
 ·
HK:0013
HUTCHMED (China)
May 28, 2026 HOLD Buy
+640.4% avg upside
6 analysts
$21.30
29.78% Upside
 ·
HCM
HUTCHMED
 May 28, 2026 HOLD Strong Buy
+208.7% avg upside
9 analysts
$13.60
32.23% Upside
 -3.4%
HK:9606
Duality Biotherapeutics, Inc.
 Nov 20, 2025 BUY Strong Buy
+136.7% avg upside
2 analysts
$493.00
166.25% Upside
 ·
HK:9926
Akeso, Inc.
 Nov 09, 2025 BUY Strong Buy
+105.6% avg upside
3 analysts
$215.00
145.49% Upside
 ·
HK:9688
Zai Lab Ltd
 Nov 06, 2025 BUY Buy
+95.8% avg upside
2 analysts
$37.44
160.79% Upside
 ·
HK:9995
RemeGen Co. Ltd. Class H
 Oct 30, 2025 HOLD Buy
-19.6% avg upside
2 analysts
$89.00
30.03% Upside
 ·
HK:2162
Keymed Biosciences, Inc.
 Sep 22, 2025 BUY Strong Buy
+62.5% avg upside
1 analyst
$93.50
62.53% Upside
 ·
HK:1952
Everest Medicines Ltd.
 Sep 22, 2025 HOLD Buy
+92.7% avg upside
3 analysts
$55.00
106.16% Upside
 ·
HK:1801
Innovent Biologics
 Sep 22, 2025 BUY Strong Buy
+33.8% avg upside
7 analysts
$123.00
61.54% Upside
 ·
ZLAB
Zai Lab
 Sep 21, 2025 BUY Strong Buy
+224.1% avg upside
13 analysts
$48.00
163.93% Upside
 -48.5%
HK:2256
Abbisko Cayman Limited
 Sep 19, 2025 BUY Strong Buy
+147.7% avg upside
3 analysts
$22.00
143.67% Upside
 ·
🔒 7 more ratings — with price targets, crowd consensus and our measured returns.
Sign in free to unlock See Pro plans
Free account unlocks every analyst's full coverage table.
Jack Lin — Frequently Asked Questions
How accurate are Jack Lin's stock ratings?
Based on the calls 13Foresight could measure, about 0% of Jack's ratings were profitable over a one-year hold, with an average return of -25.9% per rating, or -32.0% versus the S&P 500. We score every analyst the same way, from historical prices.
How is Jack ranked on 13Foresight?
Jack Lin is currently ranked unranked . Our rank blends hit rate, average return versus the market, and how many calls we have to judge — so a long, consistent record outweighs a few lucky picks. It is our own calculation, updated daily.
Which stocks does Jack cover?
Jack most recently has ratings on HK:9969, HK:0013, HCM, HK:9606, HK:9926, HK:9688, HK:9995, HK:2162, HK:1952, HK:1801, ZLAB, HK:2256. See the full coverage table above for positions, price targets and our measured returns.
Where can I see other analyst ratings?
Browse the full analyst leaderboard to compare Wall Street analysts ranked by their measured performance, success rate and average return.

Disclaimer: 13Foresight compiles analyst ratings and price targets from publicly available sources. Performance metrics, rankings and star ratings shown here are calculated independently by 13Foresight from historical market prices and may differ from figures published elsewhere. This information may be incomplete, delayed or inaccurate, is provided for research and informational purposes only, and is not investment advice. The underlying ratings and opinions are those of the respective analysts and their firms; 13Foresight accepts no liability for any decisions made based on this data.